Human Genome Sciences

Part of GSK

CompanyUnited StatesFounded 1992

RORWikidata

Human Genome Sciences develops 2 assets, the furthest approved (Benlysta in lupus nephritis). Mostly antibody acting on TNFSF13B and PRDX1; based in the United States, founded in 1992.

2
Assets
Furthest stage
Approved
27
Trials
7
Signals

Pipeline

2
  • Benlysta

    Approved, Antibody, TNFSF13B, lupus nephritis, Lupus Erythematosus, Systemic

  • raxibacumab

    Binds anthrax protective antigen, blocking toxin entry into host cells.

    Approved, Antibody, PRDX1, Anthrax, bacterial infection (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials35
  • Signals7
  • Similar companies6

Intelligence